June 25, 2024CancersOpen Access

Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression

View Full Paper

Ask AI

Bookmark

Co-targeting thioredoxin reductase and glutathione synthesis triggers synergistic cytotoxicity in epidermal growth factor receptor overexpressing glioblastoma cells.
In vitro assays of U87MG isogenic cell lines demonstrate marked glutathione depletion and elevated reactive oxygen species following combination treatment with auranofin.
Supports pro-oxidant repurposing strategies against aggressive glioblastoma tumors, though findings are limited to in vitro cell models requiring animal validation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

In vitro study reveals that co-targeting thioredoxin and glutathione pathways triggers synergistic cytotoxicity in glioblastoma cells, highlighting a pro-oxidant therapeutic strategy.

Cite This Study

Martinez-Jaramillo et al. (2024) studied this question.

synapsesocial.com/papers/68e634d8b6db6435875c6dd0 https://doi.org/10.3390/cancers16132319

View Full Paper

Ask AI

Bookmark

Implication

In vitro study reveals that co-targeting thioredoxin and glutathione pathways triggers synergistic cytotoxicity in glioblastoma cells, highlighting a pro-oxidant therapeutic strategy.

Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression

Key Points

Discussion

Implication

Cite This Study

Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider